Objective To determine the prevalence and associated features of demoralization in Parkinson disease (PD).
Demoralization is a psychological state characterized by helplessness, hopelessness, and a sense of failure. 1 The clinical hallmark of demoralization is subjective incompetence, a selfperceived incapacity to perform tasks appropriate in stressful situations. 2 Although demoralization co-occurs with depression, the two are distinct. In depression, the appropriate course of action is known, yet there is decreased motivation. Alternatively, in demoralization, there is prominent uncertainty as to the appropriate course of action. Demoralization occurs in chronic diseases such as cancer and congestive heart failure. 3 Parkinson disease (PD) is a chronic neurologic disorder, highly comorbid with depression. Patients with PD are at heightened risk for demoralization; however, demoralization has not been researched in PD. We aimed to determine the prevalence of demoralization in patients with PD and age-sex matched controls and to identify clinical correlates of demoralization in PD.
Methods

Participants
Consecutive patients with PD were recruited from the Movement Disorders Clinic (of A.P.) at Yale-New Haven Hospital, a private health care system, between June 2016 and May 2017. Control participants were frequency matched on age and sex to patients and were recruited during local senior center visits and by contacting people in the Yale Research Studies Registry, a registry of persons interested in research participation. Potential participants were told that the study aimed to assess the mental state in adults. Inclusion criteria were age of 40 to 90 years and English comprehension/literacy. Exclusion criteria included substance abuse, history of dementia, and terminal illness. Thirty-eight participants with PD who declined participation (not interested) had similar age and sex but were more likely in Hoehn and Yahr stage III or IV than control participants (39.5% vs 11.5%, p = 0.0002). Participants were diagnosed with PD by a movement disorders neurologist (A.P.) using UK Brain Bank Society criteria. 4 Questionnaires were administered to all participants in person by trained research assistants after the clinic appointment. Participants provided written informed consent approved by the Yale University Ethics Board.
Demoralization and depression assessment Demoralization was assessed with gold standard questionnaires: the Diagnostic Criteria for Psychosomatic Research, Demoralization (DCPR-D) 5 and Kissane Demoralization Scale (KDS). 6 DCPR-D consists of 4 questions: (1) Do you feel that you have failed to meet your expectations or those of other people? (2) Do you feel that you are unable to cope with pressing problems? (3) Do you experience feelings of helplessness, hopelessness, or giving up? (4) Have these feelings been present for 1 month or longer? Demoralization was defined as positive responses to questions 3 and 4 and to either question 1 or 2.
5 KDS contains 24 items that assess the frequency over the past 2 weeks that participants have had specific feelings (0-4; never to all the time) such as "I feel hopeless" and "No one can help me." Demoralization was defined as KDS score ≥24 (overall cohort mean plus 1 SD as previously used). 6 Overall, demoralization was defined as KDS score ≥24 or positive DCPR-D (as outlined above). Depression was assessed with the Patient Health Questionnaire-9 (PHQ9), which scores all 9 DSM depression criteria as 0 to 3 (not at all to nearly every day); depression was defined as PHQ9 score ≥10. 
Statistical analysis
Sample size was calculated on the basis of a demoralization estimate of 20% in PD and 5% in the general population, 10 requiring a sample size of 75 in each group. Characteristics were compared between the PD and control groups with χ 2 (categorical variables) and Student t tests (continuous variables). Logistic regression was used to determine the odds of demoralization in the overall, control, and PD cohorts separately. Forward stepwise regression was used, and potential confounding variables were entered into the final model on the basis of their association in separate bivariate analysis (p ≤ 0.10) with demoralization odds. Statistical analysis was performed with the R statistical package 3.3.2 (Auckland, New Zealand).
Data availability
Anonymized data will be shared on request with any qualified investigator.
Results
Ninety-four participants with PD (62 men, 66.0%) and 86 controls (46 men, 53.5%) enrolled during the 1-year period. The PD and control groups were comparable for age, sex, race, marital status, education, employment, economic status, and medical comorbid conditions (table 1). There was a higher prevalence of demoralization in the PD than the control group. Seventeen of 94 participants with PD were demoralized vs 7 of 86 controls (18.1% vs 8.1%, p = 0.05). Demoralization was highly associated with depression (p < 0.0001), but imperfectly. In the entire cohort, among demoralized individuals, 62.5% were depressed, and among depressed individuals, 68.2% were demoralized. There seemed to be greater depression-demoralization discordance in the PD than the control group, in which demoralized individuals were more likely depressed and depressed individuals were less likely demoralized (although these differences were not statistically significant) (table 2). In the PD group, 19 of 94 participants were depressed compared to 3 of 86 control participants (20.2% vs 3.5%, p = 0.0006). There were significantly more comorbid depressed-demoralized individuals in the PD than control group (12.8% vs 3.5%, p = 0.01).
Within the PD group, 85 participants (88.5%) were in Hoehn and Yahr stage I or II and 9 were in stage III or IV; Hoehn and Yahr staging was not associated with demoralization (data not shown). UPDRS-m score was recorded in 83 participants with PD; 71 were "on," 9 "off," and 3 were not on PD medication. Demoralized compared to nondemoralized participants with PD had significantly higher UPDRS-m scores (30.7 ± 11.3 vs 23.6 ± 11.7, p = 0.04), higher mean PHQ9 scores (12.6 ± 5.7 vs 4.1 ± 3.3, p < 0.0001), and higher mean Parkinson's Disease Questionnaire-8 scores (11.9 ± 5.0 vs 4.5 ± 3.6, p < 0.0001); there was no difference in percentage of those on medications for PD (i.e., levodopa, dopamine agonists).
In the overall cohort, logistic regression showed that PD (odds ratio 2.60, 95% confidence interval 1.00-6.80), younger age, and not being married were associated with odds of demoralization (table 3) . Among controls, only not being married was associated with demoralization odds. Among participants with PD, younger age and higher UPDRS-m score were associated with odds of demoralization. Adding antidepressant or PD medications into models for the overall or PD cohorts did not appreciably affect results. Logistic regression models for the outcome depression in participants with PD did not reveal any significantly associated factors.
Discussion
We introduce the psychological phenomenon of demoralization as it relates to PD. The main finding of our study is that demoralization is common among patients with PD, approaching 20%, which is significantly more frequent than in age-and sex-matched individuals. In the PD cohort, e Heart disease includes self-reported heart failure, coronary artery disease, or myocardial infarction. f For the economic variable, there were missing data because many participants chose not to complete this question; high is >6,000 monthly income; middle is $3,001 to $6,000 monthly income; and low is <$3,000 monthly income.
demoralization was independent of sex, education, marital status, and economic status but was associated with younger age and motor dysfunction. While demoralization was highly correlated to depression, there was discordance between depression and demoralization, most obvious in the PD cohort. Demoralized individuals without depression were present in both the PD and control groups; however, depressed individuals without demoralization were present only in the PD group. Perhaps more important, comorbid demoralization and depression were far more common among participants with PD (12.8% vs 3.5%).
In participants with PD, demoralization but not depression was associated with motor dysfunction, suggesting that demoralization more than depression is tied to functionality.
Discordance in the presence of demoralization and depression suggests that demoralization is not a simple marker of depression. It has been suggested that demoralization is better treated with cognitive behavioral therapy to address a pathologic way of thinking, rather than antidepressant medication, so distinguishing these entities is important to direct therapy. From this study, it is not clear whether demoralization results from psychological stressors that differ from those that result in depression and furthermore whether clinical or social consequences of demoralization differ from those of depression. Limitations of this study include the cross-sectional design and a lack of information regarding details of employment. In addition, patients with PD with severe disease were more likely to have declined participation; hence, we likely underestimated the prevalence of demoralization. A longitudinal study design, expanded detail in psychosocial history elements, and inclusion of patients with later-stage PD will be important to disentangle the relationships among PD, demoralization, and depression. 
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